A1AA Logo

Home
Mission Statement
What is Alpha-1
Need Help Now !
Informational Resources
  • Support
  • Medicine Support
  • Personal Advocacy
  • Education
  • Public Policy
  • Alpha-1 Vets
    Health Tips
    FAQs
    Caregivers
    Membership
    Management Team
    Press Room
    Feedback and Comment
    Our Supporters and Links
    Alpha-1 Advocacy Summary

    Won't you sign up for membership? Simply click HERE
    Joining is free, easy and private.

    to sign up and become a member of our growing community of committed individuals striving to be well informed and educated about Alpha 1.

    Read our Privacy Policy and be assured we are here to help. Let us know what we can do for YOU!
    Baxter
    Talecris
    Aventis
    Accredo Therapeutics
    Coram
    Caring Voice Coalition
    Alpha2alpha
    Testing for AAT Deficiency
    Simply click HERE
    Alpha One International Registry
    provides AAT Deficiency Testing. This AAT Deficiency Testing is a
    COMPLETE CONFIDENCIAL TESTING SERVICE
    and WITHOUT COST TO YOU.
    This testing will include measuring the CONCENTRATION of AAT in your blood, determining the TYPE of ATT in your blood and (where appropriate) determining your AAT genotype by testing the DNA in your blood; State of the art, full-spectrum Alpha-1 Testing .

    Please read the detail at: AAT Deficiency Detection Center
    Pregnancy Post- Transplant?

    From Thomas Jefferson University Heart Center, heart-lung and lung transplant recipients can have successful pregnancies

    August 2002

    Women who have received a heart, heart-lung or lung transplant are having successful pregnancies after transplantation, according to a study by researchers at Jefferson Medical College. While such pregnancies are considered "high risk," the results are encouraging, says Vincent Armenti, M.D., Ph.D., professor of surgery at Jefferson Medical College of Thomas Jefferson University in Philadelphia. The researchers compiled information through the National Pregnancy Transplantation Registry, which is based at Jefferson, from 25 transplant centers nationwide on the pregnancy outcomes of 42 female organ recipients, including 27 heart, 3 heart-lung and 12 lung transplants. There were 64 pregnancies and 43 births.

    Though there were no newborn deaths, Dr. Armenti notes that two children inherited a heart problem - mitochondrial cardiomyopathy - from the mother. Of the three groups, lung transplant patients seemed to be at the highest risk for complications during pregnancy.

    According to Dr. Armenti, in the last 11 years of studying solid organ transplant groups, women have consistently had mostly successful pregnancies with no particular pattern of birth defects. He notes, however, that higher percentages of such babies are premature or at low birth weight. He adds that mothers who have health problems going into a pregnancy generally are at greater risk to have some deterioration in health.

    "Some transplant centers have advocated waiting at least two years to become pregnant until the organ graft function is stable and the recipient can be better counseled and plan for the pregnancy," says surgery resident Scott. Cowan, M.D., of Jefferson Medical College, who presents the team's findings August 30 at the XIX International Congress of the Transplantation Society in Miami.

    Dr. Armenti hopes that by gathering such information through the registry, doctors will be able to develop patient profiles.

    The National Pregnancy Transplantation Registry (http://www.tju.edu/ntpr) was established at Thomas Jefferson University in 1991 to study the effect that pregnancy after transplantation has on the health of the mother, her transplanted organ and her baby. Through the registry, pregnancies fathered by transplant recipients are also studied. To date, the registry has gathered information on more than 2,000 pregnancies in which at least one parent is a transplant recipient.

    The study was funded by Novartis Pharmaceuticals Corporation, Fujisawa Healthcare, Inc., Roche Laboratories Inc. and Wyeth-Ayerst Pharmaceuticals, Inc.

    Additional Contact:
    Steve Benowitz
    215-955-6300


    Lking for More Information... Need Help Now! Click Here

    Return Home | Return to Education Resources | Return to Informational Resources


    Alpha-1 Advocacy Alliance, PO Box 202, 103 Rapidan Church Lane, Wolftown, VA 22748
    Telephone: 540-948-6777 or 1-866-FOR-A1AA   (1-866-367-2122) Fax # 540-948-6763

    Copyright © 2006 Alpha-1 Advocacy Alliance, All Rights Reserved

    Home | Disclaimer | Privacy Policy